February 18, 2026 – Merck, recognized exterior the US and Canada as MSD, and Mayo Clinic, introduced a analysis and growth settlement to use synthetic intelligence (AI), superior analytics and multimodal medical knowledge to help drug discovery and growth. The settlement integrates Mayo Clinic’s platform structure and medical and genomic datasets with Merck’s ambition to leverage AI-enabled digital cell applied sciences to advance illness understanding, enhance goal identification and inform early growth selections.

Leveraging the Mayo Clinic Platform, which brings collectively knowledge from Mayo Clinic US and its worldwide accomplice community in a safe surroundings, Merck will combine Mayo Clinic’s medical insights and genomic datasets, together with AI and machine studying (ML)-enabled discoveries spanning computational and spatial biology. The brand new Mayo Clinic Platform_Orchestrate program offers Merck with direct entry to Mayo Clinic’s world-class medical and scientific experience, platform knowledge together with anonymized medical and multimodal datasets, registries and biorepositories, superior AI instruments and analytics, and the flexibility to scale options.

Beneath the settlement, which marks Mayo Clinic’s first strategic collaboration of this scale with a world biopharmaceutical firm, Merck will leverage Mayo Clinic’s in depth multimodal knowledge – together with laboratory outcomes, medical imaging, medical notes and molecular knowledge – to help the validation of AI fashions and assist translate analysis insights into discovery and growth methods.

Proceed studying